Pub Date : 2023-09-29DOI: 10.33371/ijoc.v17i3.1051
Sita Andarini, Andintia Aisyah Santoso, Mochammad Aris Arfiansyah, Ginanjar Arum Desianti, Muflih Adil Hanif, Arif Riswahyudi Hanafi, Sutji Mariono
Background: ALK-positive Non-Small Cell Lung Cancer (NSCLC) is a rare condition predominantly observed in much younger non-smokers with adenocarcinoma histology, often accompanied by brain metastases. Despite its unique features, there is a lack of data concerning the treatment of ALK-positive NSCLC in Indonesia. Therefore, this study represented the first attempt to document the treatment landscape for ALK-positive NSCLC in the country. The available ALK inhibitors included crizotinib, alectinib, brigatinib, and lorlatinib, and none of these were listed under the Indonesian Universal Health Coverage as of September 2022. This study aimed to characterize survival outcomes of ALK-positive NSCLC patients treated within a specialized thoracic oncology practice in Indonesia.Methods: The retrospective observational cohort study drew secondary data from medical records of ALK-positive NSCLC patients treated at a private thoracic oncology clinic. Data were collected retrospectively, spanning from December 2019 to December 31, 2022. Exclusion criteria included incomplete data, untreated ALK-positive NSCLC, cases at stage I-III, or diagnoses made after August 2021. The observation period extended up to 36 months, although several patients exceeded 48 months, with one individual currently boasting a 96-month survival.Results: A total of 15 patients with ALK-positive NSCLC were selected as the respondents in this study. The median age stood at 50.8 years, predominantly female, and diagnosed with adenocarcinoma. Predominant sites of metastasis included pleural effusion and brain metastases, and preliminary 36-month survival rates reached 73.3%. The 1-year survival rate was recorded at 100%, while the 2-year overall survival (OS) stood at 80%, aligning closely with global ALK inhibitors clinical trial data.Conclusions: This study provided the first-ever dataset indicating an ALK-positive profile within a singular thoracic oncology clinic in Indonesia. Despite the accessibility constraints of treatments, ALK-positive patients showed comparable total survival to pivotal clinical trial data. This preliminary dataset shed light on the profile and treatment of ALK-positive NSCLC in the country.
{"title":"Three-Year Overall Survival of Advanced Stage ALK-Positive NSCLC at a Single Clinical Setting in Indonesia","authors":"Sita Andarini, Andintia Aisyah Santoso, Mochammad Aris Arfiansyah, Ginanjar Arum Desianti, Muflih Adil Hanif, Arif Riswahyudi Hanafi, Sutji Mariono","doi":"10.33371/ijoc.v17i3.1051","DOIUrl":"https://doi.org/10.33371/ijoc.v17i3.1051","url":null,"abstract":"Background: ALK-positive Non-Small Cell Lung Cancer (NSCLC) is a rare condition predominantly observed in much younger non-smokers with adenocarcinoma histology, often accompanied by brain metastases. Despite its unique features, there is a lack of data concerning the treatment of ALK-positive NSCLC in Indonesia. Therefore, this study represented the first attempt to document the treatment landscape for ALK-positive NSCLC in the country. The available ALK inhibitors included crizotinib, alectinib, brigatinib, and lorlatinib, and none of these were listed under the Indonesian Universal Health Coverage as of September 2022. This study aimed to characterize survival outcomes of ALK-positive NSCLC patients treated within a specialized thoracic oncology practice in Indonesia.Methods: The retrospective observational cohort study drew secondary data from medical records of ALK-positive NSCLC patients treated at a private thoracic oncology clinic. Data were collected retrospectively, spanning from December 2019 to December 31, 2022. Exclusion criteria included incomplete data, untreated ALK-positive NSCLC, cases at stage I-III, or diagnoses made after August 2021. The observation period extended up to 36 months, although several patients exceeded 48 months, with one individual currently boasting a 96-month survival.Results: A total of 15 patients with ALK-positive NSCLC were selected as the respondents in this study. The median age stood at 50.8 years, predominantly female, and diagnosed with adenocarcinoma. Predominant sites of metastasis included pleural effusion and brain metastases, and preliminary 36-month survival rates reached 73.3%. The 1-year survival rate was recorded at 100%, while the 2-year overall survival (OS) stood at 80%, aligning closely with global ALK inhibitors clinical trial data.Conclusions: This study provided the first-ever dataset indicating an ALK-positive profile within a singular thoracic oncology clinic in Indonesia. Despite the accessibility constraints of treatments, ALK-positive patients showed comparable total survival to pivotal clinical trial data. This preliminary dataset shed light on the profile and treatment of ALK-positive NSCLC in the country.","PeriodicalId":13489,"journal":{"name":"Indonesian Journal of Cancer","volume":"6 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135247679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: An adverse normal tissue response, such as normal tissue toxicity (NTT), is present in radiotherapy (RT) patients and can limit the effectiveness of the RT treatment. Identifying patients with adverse tissue responses before RT had clinical benefits and individual radiosensitivity (IRS) is considered an important factor in NTT incidences. Therefore, this systematic study aimed to determine the possibility of using phosphorylated Ataxia Telangiectasia Mutated (pATM) Enzyme-Linked Immunosorbent Assay (ELISA) to predict NTT in RT patients.Methods: A comprehensive data search was conducted in three electronic databases, namely PUBMED CENTRAL, ScienceDirect, and SCOPUS. The quality of relevant publications was independently evaluated using the PICO (participants, intervention/exposure, comparison, and outcome) approach.Results: : A total of 47 articles were retrieved, 41 of which were assessed based on the titles and abstracts. Furthermore, 39 articles were excluded, and 2 were included in this study.Conclusions: The phosphorylated ATM ELISA on lymphocytes showed promising results for IRS prediction in RT patients. However, these assumptions should be validated on a larger RT patient cohort.
{"title":"Phosphorylated Ataxia Telangiectasia Mutated (pATM) Enzyme-Linked Immunosorbent Assay (ELISA) for Predicting Radiation Induces Normal Tissue Toxicity in Radiotherapy Patients: A Systematic Review","authors":"Sofiati Purnami, Viria Agesti Suvifan, Dwi Ramadhani, Yanti Lusiyanti, Darlina Darlina, Nastiti Rahajeng, Mukh Syaifudin, Dwi Ari Pujianto, Retno Widowati","doi":"10.33371/ijoc.v17i3.971","DOIUrl":"https://doi.org/10.33371/ijoc.v17i3.971","url":null,"abstract":"Background: An adverse normal tissue response, such as normal tissue toxicity (NTT), is present in radiotherapy (RT) patients and can limit the effectiveness of the RT treatment. Identifying patients with adverse tissue responses before RT had clinical benefits and individual radiosensitivity (IRS) is considered an important factor in NTT incidences. Therefore, this systematic study aimed to determine the possibility of using phosphorylated Ataxia Telangiectasia Mutated (pATM) Enzyme-Linked Immunosorbent Assay (ELISA) to predict NTT in RT patients.Methods: A comprehensive data search was conducted in three electronic databases, namely PUBMED CENTRAL, ScienceDirect, and SCOPUS. The quality of relevant publications was independently evaluated using the PICO (participants, intervention/exposure, comparison, and outcome) approach.Results: : A total of 47 articles were retrieved, 41 of which were assessed based on the titles and abstracts. Furthermore, 39 articles were excluded, and 2 were included in this study.Conclusions: The phosphorylated ATM ELISA on lymphocytes showed promising results for IRS prediction in RT patients. However, these assumptions should be validated on a larger RT patient cohort.","PeriodicalId":13489,"journal":{"name":"Indonesian Journal of Cancer","volume":"59 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135247957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Breast cancer is the most common malignancy in women globally. In Indonesia, a total of 65,858 new cases with a 22,530 mortality rate were reported in 2020. To overcome this health condition, surgery serves as the primary treatment, with post-mastectomy complications frequently involving seroma formation, exacerbating post-operative problems. Therefore, this study aimed to assess the total drain volume in post-MRM breast cancer patients using Songket incision compared to Stewart incision plus axillary anchor. This experiment was conducted to determine the optimal surgical option for breast cancer patients.Methods: A two-arm randomized controlled trial was conducted in female patients with breast cancer treated at the Surgical Oncology Division of Mohammad Hoesin Hospital Palembang between April to May 2022. Patients were blindly assigned to one of the two arms, namely the Songket incision and Stewart incision plus an axillary anchor. The eligible sample consisted of patients diagnosed with breast cancer who were slated for Modified Radical Mastectomy (MRM) surgery, willing to participate, and signed informed consent. The primary outcome of this study was total drain volume, while the secondary objective encompassed the length of treatment selected.Results: A total of 26 patients participated in this study (n=13 in each arm). The total drain volume using the Stewart incision was 378.07 ± 219.57, compared to 174.23 ± 97.44 ml for the Songket design (p< 0.001). The mean length of treatment was 4.46 ± 0.77 days in the Stewart incision plus axillary anchor group and 3.23 ± 0.43 days in the Songket incision design (p < 0.001). Conclusions: Songket incision was the best surgical option for breast cancer patients.
背景:乳腺癌是全球女性中最常见的恶性肿瘤。在印度尼西亚，2020年共报告了65,858例新病例，其中22,530例死亡。为了克服这种健康状况，手术是主要的治疗方法，乳房切除术后的并发症经常包括血清肿形成，加剧了术后问题。因此，本研究旨在评估mrm后乳腺癌患者采用Songket切口与Stewart切口加腋窝锚的总引流量。本实验旨在确定乳腺癌患者的最佳手术选择。方法:在2022年4月至5月期间，在Mohammad Hoesin医院巨港外科肿瘤科接受治疗的女性乳腺癌患者中进行了一项两组随机对照试验。患者被盲目分配到两个臂中的一个，即Songket切口和Stewart切口加腋窝锚。符合条件的样本包括诊断为乳腺癌的患者，他们计划进行改良根治性乳房切除术(MRM)手术，愿意参加，并签署知情同意书。本研究的主要结果是总引流量，而次要目标包括所选择的治疗时间。结果:共有26例患者参与了本研究(每组n=13)。Stewart切口的总引流量为378.07±219.57 ml，而Songket设计的总引流量为174.23±97.44 ml (p<0.001)。Stewart切口加腋锚组的平均治疗时间为4.46±0.77天，Songket切口组的平均治疗时间为3.23±0.43天(p <0.001)。结论:松ket切口是乳腺癌患者的最佳手术选择。
{"title":"A Randomized Trial of Total Drain Volume in Post-Modified Radical Mastectomy (MRM) Breast Cancer Patient Using Songket Incision Compare to Stewart Incision plus Axillary Anchor at Dr. Mohammad Hoesin Hospital Palembang","authors":"Meigi Medika, Nur Qodir","doi":"10.33371/ijoc.v17i3.981","DOIUrl":"https://doi.org/10.33371/ijoc.v17i3.981","url":null,"abstract":"Background: Breast cancer is the most common malignancy in women globally. In Indonesia, a total of 65,858 new cases with a 22,530 mortality rate were reported in 2020. To overcome this health condition, surgery serves as the primary treatment, with post-mastectomy complications frequently involving seroma formation, exacerbating post-operative problems. Therefore, this study aimed to assess the total drain volume in post-MRM breast cancer patients using Songket incision compared to Stewart incision plus axillary anchor. This experiment was conducted to determine the optimal surgical option for breast cancer patients.Methods: A two-arm randomized controlled trial was conducted in female patients with breast cancer treated at the Surgical Oncology Division of Mohammad Hoesin Hospital Palembang between April to May 2022. Patients were blindly assigned to one of the two arms, namely the Songket incision and Stewart incision plus an axillary anchor. The eligible sample consisted of patients diagnosed with breast cancer who were slated for Modified Radical Mastectomy (MRM) surgery, willing to participate, and signed informed consent. The primary outcome of this study was total drain volume, while the secondary objective encompassed the length of treatment selected.Results: A total of 26 patients participated in this study (n=13 in each arm). The total drain volume using the Stewart incision was 378.07 ± 219.57, compared to 174.23 ± 97.44 ml for the Songket design (p< 0.001). The mean length of treatment was 4.46 ± 0.77 days in the Stewart incision plus axillary anchor group and 3.23 ± 0.43 days in the Songket incision design (p < 0.001). Conclusions: Songket incision was the best surgical option for breast cancer patients.","PeriodicalId":13489,"journal":{"name":"Indonesian Journal of Cancer","volume":"94 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135247955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dea Putri Audina, Sita Laksmi Andarini, Hana Khairina Putri Faisal, Prasenohadi Prasenohadi, Jamal Zaini, Herawati Hidajat
Introduction: Pulmonary tuberculosis (TB) and malignancy are conditions with similar respiratory diseases and they are even known to coexist simultaneously. Therefore, accurate diagnosis of each disease is crucial to ensure precise treatment. This case study showed the coexistence of pulmonary TB and primary pulmonary sarcoma.Case Presentation: A 62-year-old male presented with a 3-month history of dyspnea, which worsened within 3 days. Before hospitalization, there were complaints of left chest pain, fatigue, loss of appetite, weight loss within 5 months, and night sweats. The patient who was a heavy smoker had experienced hemoptysis in the past 5 months. Upon physical examination, an increased respiratory rate and decreased oxygen saturation level. Furthermore, there were asymmetrical thorax movements, dull percussion on the left side, and decreased vesicular breathing sound on the left hemithorax, with no rhonchi or wheezing. A chest x-ray showed a destroyed left lung, while scanning confirmed left lung atelectasis and indicated a suspected mass within or around the left bronchus causing total obstruction in the main left bronchus. The bronchoscopy procedure identified a mass blocking the left main bronchus. However, a biopsy yielded inconclusive results. A rapid molecular test of TB detected Mycobacterium tuberculosis, which was discovered to be Rifampicin sensitive. As a result, the patient was treated daily with 4 fixed drug combinations for anti-TB. Despite the treatment, the complaint was not resolved within the next 3 months, as there was still a disease of cough in the form of mass-like phlegm, which uncovered a malignancy focus cell with differential diagnosis of pleomorphic sarcoma and sarcomatoid carcinoma.Conclusions: Lung malignancy not only overlapped with but also occurred simultaneously alongside lung TB. Therefore, it was crucial to establish a clear diagnosis in patients with chronic respiratory disease.
{"title":"Primary Pulmonary Sarcoma Coinfected with Pulmonary Tuberculosis: A Case Report","authors":"Dea Putri Audina, Sita Laksmi Andarini, Hana Khairina Putri Faisal, Prasenohadi Prasenohadi, Jamal Zaini, Herawati Hidajat","doi":"10.33371/ijoc.v17i3.991","DOIUrl":"https://doi.org/10.33371/ijoc.v17i3.991","url":null,"abstract":"Introduction: Pulmonary tuberculosis (TB) and malignancy are conditions with similar respiratory diseases and they are even known to coexist simultaneously. Therefore, accurate diagnosis of each disease is crucial to ensure precise treatment. This case study showed the coexistence of pulmonary TB and primary pulmonary sarcoma.Case Presentation: A 62-year-old male presented with a 3-month history of dyspnea, which worsened within 3 days. Before hospitalization, there were complaints of left chest pain, fatigue, loss of appetite, weight loss within 5 months, and night sweats. The patient who was a heavy smoker had experienced hemoptysis in the past 5 months. Upon physical examination, an increased respiratory rate and decreased oxygen saturation level. Furthermore, there were asymmetrical thorax movements, dull percussion on the left side, and decreased vesicular breathing sound on the left hemithorax, with no rhonchi or wheezing. A chest x-ray showed a destroyed left lung, while scanning confirmed left lung atelectasis and indicated a suspected mass within or around the left bronchus causing total obstruction in the main left bronchus. The bronchoscopy procedure identified a mass blocking the left main bronchus. However, a biopsy yielded inconclusive results. A rapid molecular test of TB detected Mycobacterium tuberculosis, which was discovered to be Rifampicin sensitive. As a result, the patient was treated daily with 4 fixed drug combinations for anti-TB. Despite the treatment, the complaint was not resolved within the next 3 months, as there was still a disease of cough in the form of mass-like phlegm, which uncovered a malignancy focus cell with differential diagnosis of pleomorphic sarcoma and sarcomatoid carcinoma.Conclusions: Lung malignancy not only overlapped with but also occurred simultaneously alongside lung TB. Therefore, it was crucial to establish a clear diagnosis in patients with chronic respiratory disease.","PeriodicalId":13489,"journal":{"name":"Indonesian Journal of Cancer","volume":"55 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135247958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dewi Wulandari, Tarafainy Basalamah, Diyah Eka Andayani
Background: Cervical cancer is the 4th most prevalent among women worldwide and ranks as the 4th leading cause of cancer-related death. During radiotherapy for this disease, about 80% of patients experience diarrhea or radiation-induced diarrhea (RID) which can significantly compromise quality of life and disrupt the continuity of the therapy when left untreated. Furthermore, it was reported that probiotics exhibit promising efficacy in preventing the incidence of RID, but the conclusive nature of this investigation remains uncertain. This study aimed to determine the effectiveness of probiotics in preventing the incidence of diarrhea in cervical cancer patients receiving radiotherapy.Methods: A comprehensive search was conducted on 4 large databases, namely Pubmed, PMC, Cochrane Library, and EMBASE, adhering to the eligibility criteria. Results: Following the application of the stipulated eligibility criteria, 2 articles were obtained, namely Systematic Reviews/Metaanalysis (SR/MA) and Randomized Control Trial (RCT). The risk ratio of diarrhea incidence in cervical cancer patients who were administered probiotics while receiving radiotherapy was 0.61 (CI 95% 0.46-0.81, p=0.0007). The therapeutic effect was most pronounced when Lactobacillus acidophilus and Bifidobacterial strains, were given 3 times daily. Conclusions: The administration of probiotics proved to be a valuable strategy in preventing the incidence of diarrhea in cervical cancer patients receiving radiotherapy
{"title":"The Administration of Probiotics to Prevent Diarrhea in Cervical Cancer Patients Undergoing Radiotherapy: A Literature Review","authors":"Dewi Wulandari, Tarafainy Basalamah, Diyah Eka Andayani","doi":"10.33371/ijoc.v17i3.983","DOIUrl":"https://doi.org/10.33371/ijoc.v17i3.983","url":null,"abstract":"Background: Cervical cancer is the 4th most prevalent among women worldwide and ranks as the 4th leading cause of cancer-related death. During radiotherapy for this disease, about 80% of patients experience diarrhea or radiation-induced diarrhea (RID) which can significantly compromise quality of life and disrupt the continuity of the therapy when left untreated. Furthermore, it was reported that probiotics exhibit promising efficacy in preventing the incidence of RID, but the conclusive nature of this investigation remains uncertain. This study aimed to determine the effectiveness of probiotics in preventing the incidence of diarrhea in cervical cancer patients receiving radiotherapy.Methods: A comprehensive search was conducted on 4 large databases, namely Pubmed, PMC, Cochrane Library, and EMBASE, adhering to the eligibility criteria. Results: Following the application of the stipulated eligibility criteria, 2 articles were obtained, namely Systematic Reviews/Metaanalysis (SR/MA) and Randomized Control Trial (RCT). The risk ratio of diarrhea incidence in cervical cancer patients who were administered probiotics while receiving radiotherapy was 0.61 (CI 95% 0.46-0.81, p=0.0007). The therapeutic effect was most pronounced when Lactobacillus acidophilus and Bifidobacterial strains, were given 3 times daily. Conclusions: The administration of probiotics proved to be a valuable strategy in preventing the incidence of diarrhea in cervical cancer patients receiving radiotherapy","PeriodicalId":13489,"journal":{"name":"Indonesian Journal of Cancer","volume":"59 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135247669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: : Gestational trophoblastic disease (GTD) is a heterogeneous group of lesions caused by abnormal trophoblast proliferation and the malignant form is called gestational trophoblastic neoplasia (GTN). Dr. Hasan Sadikin General Hospital, located in Bandung, West Java, is one of the main cancer referral hospitals in Indonesia. Consequently, the characteristics of GTN patients in this hospital can represent the general population in the province. This study aimed to elaborate on the characteristics of referral patients with GTN in Dr. Hasan Sadikin General Hospital.Methods: : Medical records of post-molar GTN patients in Dr. Hasan Sadikin General Hospital from between January 2019 to December 2020 were collected and analyzed. GTN was diagnosed according to the International Federation in Gynecology and Obstetrics (FIGO) criteria. Additionally, both the sociodemographic and clinical characteristics of patients were evaluated.Results: The results showed that among the 160 participants in this study, the overall mean age was 33±8.7 years, with a mean βhCG level of 241,461.81±630,557.90 mIU/mL. Moreover, approximately 16.3% had gestosis and 5% were diagnosed with hyperthyroidism. The majority of post-molar observations at the hospital were not carried out according to standards, with only 8.1% of patients receiving optimal surveillance. About 56.8% visited the hospital due to vaginal bleeding, while most histopathological results showed complete hydatidiform moles (44.4%), and choriocarcinomas (16.3%). Most of the patients were diagnosed as stage I (81.9%), had lowrisk FIGO scores (80.6%), and were treated with methotrexate (80.6%).Conclusions: GTN patients in Dr. Hasan Sadikin General Hospital showed clinical characteristics consistent with previous studies. The low percentage of patients receiving optimal post-molar surveillance could cause delayed referral. This suboptimal surveillance might be due to the high cost of βhCG testing, lack of facilities, and low patient compliance in West Java
背景:妊娠滋养细胞病(GTD)是一种由滋养细胞异常增殖引起的异质性病变，其恶性形式称为妊娠滋养细胞瘤(GTN)。Hasan Sadikin医生总医院位于西爪哇万隆，是印度尼西亚主要的癌症转诊医院之一。因此，该院GTN患者的特点可以代表全省的一般人群。本研究旨在阐述哈桑·萨迪金医生总医院转诊GTN患者的特点。方法:收集2019年1月至2020年12月哈桑·萨迪金总医院后磨牙GTN患者的医疗记录并进行分析。GTN是根据国际妇产科学联合会(FIGO)的标准诊断的。此外，还对患者的社会人口学和临床特征进行了评估。结果:本研究160例参与者的总体平均年龄为33±8.7岁，平均βhCG水平为241,461.81±630,557.90 mIU/mL。此外，大约16.3%的人有妊娠，5%的人被诊断为甲状腺功能亢进。医院的大多数磨牙后观察没有按照标准进行，只有8.1%的患者接受了最佳监测。56.8%的患者因阴道出血就诊，而组织病理学结果显示大部分为完全包虫状痣(44.4%)和绒毛膜癌(16.3%)。大多数患者诊断为I期(81.9%)，FIGO评分低危(80.6%)，接受甲氨蝶呤治疗(80.6%)。结论:Dr. Hasan Sadikin总医院GTN患者的临床特征与既往研究一致。接受最佳臼齿后监测的患者比例低可能导致转诊延迟。这种不理想的监测可能是由于βhCG检测的高成本，缺乏设备，以及西爪哇患者依从性低
{"title":"Characteristics of Referral Patients with Gestational Trophoblastic Neoplasia in Dr. Hasan Sadikin General Hospital Bandung","authors":"Kemala Isnainiasih Mantilidewi, Aditya Rifandi Zaenudin, Ali Budi Harsono, Anita Deborah Anwar, Jessica Kireina","doi":"10.33371/ijoc.v17i3.990","DOIUrl":"https://doi.org/10.33371/ijoc.v17i3.990","url":null,"abstract":"Background: : Gestational trophoblastic disease (GTD) is a heterogeneous group of lesions caused by abnormal trophoblast proliferation and the malignant form is called gestational trophoblastic neoplasia (GTN). Dr. Hasan Sadikin General Hospital, located in Bandung, West Java, is one of the main cancer referral hospitals in Indonesia. Consequently, the characteristics of GTN patients in this hospital can represent the general population in the province. This study aimed to elaborate on the characteristics of referral patients with GTN in Dr. Hasan Sadikin General Hospital.Methods: : Medical records of post-molar GTN patients in Dr. Hasan Sadikin General Hospital from between January 2019 to December 2020 were collected and analyzed. GTN was diagnosed according to the International Federation in Gynecology and Obstetrics (FIGO) criteria. Additionally, both the sociodemographic and clinical characteristics of patients were evaluated.Results: The results showed that among the 160 participants in this study, the overall mean age was 33±8.7 years, with a mean βhCG level of 241,461.81±630,557.90 mIU/mL. Moreover, approximately 16.3% had gestosis and 5% were diagnosed with hyperthyroidism. The majority of post-molar observations at the hospital were not carried out according to standards, with only 8.1% of patients receiving optimal surveillance. About 56.8% visited the hospital due to vaginal bleeding, while most histopathological results showed complete hydatidiform moles (44.4%), and choriocarcinomas (16.3%). Most of the patients were diagnosed as stage I (81.9%), had lowrisk FIGO scores (80.6%), and were treated with methotrexate (80.6%).Conclusions: GTN patients in Dr. Hasan Sadikin General Hospital showed clinical characteristics consistent with previous studies. The low percentage of patients receiving optimal post-molar surveillance could cause delayed referral. This suboptimal surveillance might be due to the high cost of βhCG testing, lack of facilities, and low patient compliance in West Java","PeriodicalId":13489,"journal":{"name":"Indonesian Journal of Cancer","volume":"24 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135247839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: Desmoid tumor is a benign growth that can exhibit aggressiveness and various patterns, resulting in a wide range of management methods. These methods include observation to active interventions, such as surgery, radiation, and systemic therapy. Therefore, this case report aimed to present the role of radiation therapy for desmoid tumors in a young girl who refused limb amputation to preserve the organ.Case Presentation: This study presented the case of a 13-year-old girl with a vast and painful desmoid tumor in the left upper arm. Magnetic resonance imaging (MRI) on the left shoulder showed an 8 x 9 x 17 cm solid soft tissue mass on the left deltoid muscle with the necrotic component that expands to adjacent cutaneous and subcutaneous tissue. In this case, the left humerus attaches to the deep brachial artery and vein. Previous pathological studies with immunohistochemicals showed desmoid fibromatosis. A multidisciplinary team discussion led to the selection of, radiotherapy for treatment because of tumor localization and proximity to the critical structure. Radiation was also selected as the definitive therapy of choice with the aim of local control and organ preservation. Furthermore, the radiation dose was 56 Gy in 2 Gy per fraction over six weeks. After six months of follow-up, the patient reported pain relief, improved range of motion, and reduced tumor size.Conclusion: Radiotherapy reduced desmoid tumor size and improved symptoms without compromising organ function in young girls.
硬纤维瘤是一种具有侵袭性和多种形态的良性肿瘤，因此治疗方法广泛。这些方法包括观察到积极干预，如手术、放疗和全身治疗。因此，本病例报告旨在介绍放射治疗在一个拒绝截肢以保存器官的年轻女孩的硬纤维瘤中的作用。病例介绍:本研究报告一名13岁女孩在左上臂有巨大且疼痛的硬纤维瘤。左肩磁共振成像(MRI)显示左侧三角肌有一个8 x 9 x 17厘米的实性软组织肿块，坏死成分扩展到邻近的皮肤和皮下组织。在这种情况下，左肱骨连接到肱深动脉和静脉。先前的免疫组化病理研究显示纤维瘤病。多学科小组讨论导致选择放射治疗，因为肿瘤的定位和接近的关键结构。为了局部控制和器官保存，放疗也被选为最终的治疗选择。此外，辐射剂量为56 Gy / 2 Gy / 6周。六个月的随访后，患者报告疼痛缓解，活动范围改善，肿瘤大小缩小。结论:在不影响器官功能的情况下，放疗可减小女孩硬纤维瘤的大小，改善症状。
{"title":"A Case Report of Radiation Therapy as Definitive Treatment for Desmoid Tumor in a Young Girl","authors":"Rafiq Sulistyo Nugroho, Irma Darinafitri, Eviana Norahmawati, Istan Irmansyah Irsan, Satria Pandu Persada Isma","doi":"10.33371/ijoc.v17i3.977","DOIUrl":"https://doi.org/10.33371/ijoc.v17i3.977","url":null,"abstract":"Introduction: Desmoid tumor is a benign growth that can exhibit aggressiveness and various patterns, resulting in a wide range of management methods. These methods include observation to active interventions, such as surgery, radiation, and systemic therapy. Therefore, this case report aimed to present the role of radiation therapy for desmoid tumors in a young girl who refused limb amputation to preserve the organ.Case Presentation: This study presented the case of a 13-year-old girl with a vast and painful desmoid tumor in the left upper arm. Magnetic resonance imaging (MRI) on the left shoulder showed an 8 x 9 x 17 cm solid soft tissue mass on the left deltoid muscle with the necrotic component that expands to adjacent cutaneous and subcutaneous tissue. In this case, the left humerus attaches to the deep brachial artery and vein. Previous pathological studies with immunohistochemicals showed desmoid fibromatosis. A multidisciplinary team discussion led to the selection of, radiotherapy for treatment because of tumor localization and proximity to the critical structure. Radiation was also selected as the definitive therapy of choice with the aim of local control and organ preservation. Furthermore, the radiation dose was 56 Gy in 2 Gy per fraction over six weeks. After six months of follow-up, the patient reported pain relief, improved range of motion, and reduced tumor size.Conclusion: Radiotherapy reduced desmoid tumor size and improved symptoms without compromising organ function in young girls.","PeriodicalId":13489,"journal":{"name":"Indonesian Journal of Cancer","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135247842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-29DOI: 10.33371/ijoc.v17i3.1061
Agus Susanto Kosasih, Arif Riswahyudi Riswahyudi Hanafi, Ninik Sukartini, Mariska Pangaribunan, Muhammad Alfin Hanif, Willy Pandu Ariawan Pandu Ariawan, Sri Agustini Kurniawati, Dian Cahyanti, Kartika Anastasia Kosasih, Alyssa Diandra, Markus Yovian, Lyana Setiawan
Background: The development of new biomarker-targeted therapies is associated with the improvements in overall survival of advanced non-small cell lung cancer (NSCLC) sufferers. However, tissue biopsy as the gold standard to determine tumor molecular status is not always feasible in advanced diseases. Liquid biopsy, a minimally invasive technique to obtain cytological and molecular assessment from patients allows real-time monitoring of tumors and identification of resistant mechanisms. Therefore, this preliminary study aimed to compare the molecular profile of advanced NSCLC from liquid and tissue biopsy.Methods: This cross-sectional study was conducted on patients with NSCLC undergoing diagnostic procedures at Dharmais National Cancer Center Hospital from January 2018 to December 2021. Tissue biopsy to check epidermal growth factor receptor (EGFR) mutations was performed on formalin-fixed paraffin-embedded (FFPE) tissue blocks. Analysis of mutations involved using a home-brew polymerase chain reaction (PCR) based on a high-resolution melting technique. Meanwhile, the liquid biopsy was performed using blood samples, and sequencing for circulating tumor DNA (ctDNA) was carried out with NGS.Results: : The results showed that among the 22 subjects enrolled in the study, tissue biopsy identified wild-type EGFR in 18 (81.8%), exon 19 mutations in 3, and exon 21 mutations (L861Q and L858R) in 3. Liquid biopsy found EGFR exon 19 deletions in 11 samples (50%), exon 21 mutations (L861Q and L858R) in 10, L861Q in 7, L8585 in 6, and wild type in 1 sample. Additionally, acquired EGFR mutations in exon 20 T790M were found in 5 samples.Conclusions: Liquid biopsy may be beneficial in patients for whom tissue biopsy cannot be performed or where tissue for molecular profiling is inadequate. This modality can also be used to detect molecular resistance in patients with advanced NSCLC.
{"title":"The Role of Liquid Biopsy for Detecting Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) – A Preliminary Study in Indonesian Population","authors":"Agus Susanto Kosasih, Arif Riswahyudi Riswahyudi Hanafi, Ninik Sukartini, Mariska Pangaribunan, Muhammad Alfin Hanif, Willy Pandu Ariawan Pandu Ariawan, Sri Agustini Kurniawati, Dian Cahyanti, Kartika Anastasia Kosasih, Alyssa Diandra, Markus Yovian, Lyana Setiawan","doi":"10.33371/ijoc.v17i3.1061","DOIUrl":"https://doi.org/10.33371/ijoc.v17i3.1061","url":null,"abstract":"Background: The development of new biomarker-targeted therapies is associated with the improvements in overall survival of advanced non-small cell lung cancer (NSCLC) sufferers. However, tissue biopsy as the gold standard to determine tumor molecular status is not always feasible in advanced diseases. Liquid biopsy, a minimally invasive technique to obtain cytological and molecular assessment from patients allows real-time monitoring of tumors and identification of resistant mechanisms. Therefore, this preliminary study aimed to compare the molecular profile of advanced NSCLC from liquid and tissue biopsy.Methods: This cross-sectional study was conducted on patients with NSCLC undergoing diagnostic procedures at Dharmais National Cancer Center Hospital from January 2018 to December 2021. Tissue biopsy to check epidermal growth factor receptor (EGFR) mutations was performed on formalin-fixed paraffin-embedded (FFPE) tissue blocks. Analysis of mutations involved using a home-brew polymerase chain reaction (PCR) based on a high-resolution melting technique. Meanwhile, the liquid biopsy was performed using blood samples, and sequencing for circulating tumor DNA (ctDNA) was carried out with NGS.Results: : The results showed that among the 22 subjects enrolled in the study, tissue biopsy identified wild-type EGFR in 18 (81.8%), exon 19 mutations in 3, and exon 21 mutations (L861Q and L858R) in 3. Liquid biopsy found EGFR exon 19 deletions in 11 samples (50%), exon 21 mutations (L861Q and L858R) in 10, L861Q in 7, L8585 in 6, and wild type in 1 sample. Additionally, acquired EGFR mutations in exon 20 T790M were found in 5 samples.Conclusions: Liquid biopsy may be beneficial in patients for whom tissue biopsy cannot be performed or where tissue for molecular profiling is inadequate. This modality can also be used to detect molecular resistance in patients with advanced NSCLC.","PeriodicalId":13489,"journal":{"name":"Indonesian Journal of Cancer","volume":"22 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135247672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-29DOI: 10.33371/ijoc.v17i3.1047
Angeline Maranata, Tantri Hellyanti, Ria Kodariah
Background: The Mesenchymal-Epithelial Transition factor (C-Met) is a tyrosine kinase receptor (TKR) that binds to a ligand called Hepatocyte Growth Factor (HGF). Recent studies conducted on patients with epithelial ovarian cancer (EOC) reported that high expression of C-Met was associated with poorer clinicopathological grading and outcomes. Therefore, this study aimed to further explore the downstream pathway specifically activated when the HGF/C-Met complex was formed, the interplay between C-Met and other molecules, as well as the impact on EOC when these interactions were inhibited through designated molecular targeted therapy.Methods: The search strategy using the PubMed search engine (https://pubmed.ncbi.nlm.nih.gov/) was conducted on September 21, 2022, with the keywords: “HGF/C-Met and ovarian cancer”. The search resulted in 261 articles, and they were filtered by “published in the last five years,” which yielded 67 articles. These articles then underwent further screening, resulting in 40 articles for analysis. A systematic literature review was conducted to improve the quality of this study. Approximately 150 articles were thoroughly examined and organized using a reference manager, then 15 with the greatest impact and clinical relevance to this study were selected. Results: The HGF/C-Met complex was found to stimulate signaling pathways linked to the growth of epithelial cells and also caused the phosphorylation of tyrosine residues on other tyrosine receptors. The activation of C-Met affected the downstream pathways involving molecules associated with cell proliferation and survival, such as epidermal growth factor receptor (EGFR), p53, and KRAS. C-Met can be combined with other tyrosine kinase inhibitors in chemotherapy to enhance the initiation of cell death (apoptosis) in cancer cells.Conclusions: The HGF/C-Met mediated a signaling cascade that played an essential role in the tumorigenesis of ovarian carcinoma and had the potential to be a targeted molecular therapy in EOC
{"title":"HGF/C-Met Expression in Epithelial Ovarian Carcinogenesis and Its Potential as Molecular Targeted Therapy","authors":"Angeline Maranata, Tantri Hellyanti, Ria Kodariah","doi":"10.33371/ijoc.v17i3.1047","DOIUrl":"https://doi.org/10.33371/ijoc.v17i3.1047","url":null,"abstract":"Background: The Mesenchymal-Epithelial Transition factor (C-Met) is a tyrosine kinase receptor (TKR) that binds to a ligand called Hepatocyte Growth Factor (HGF). Recent studies conducted on patients with epithelial ovarian cancer (EOC) reported that high expression of C-Met was associated with poorer clinicopathological grading and outcomes. Therefore, this study aimed to further explore the downstream pathway specifically activated when the HGF/C-Met complex was formed, the interplay between C-Met and other molecules, as well as the impact on EOC when these interactions were inhibited through designated molecular targeted therapy.Methods: The search strategy using the PubMed search engine (https://pubmed.ncbi.nlm.nih.gov/) was conducted on September 21, 2022, with the keywords: “HGF/C-Met and ovarian cancer”. The search resulted in 261 articles, and they were filtered by “published in the last five years,” which yielded 67 articles. These articles then underwent further screening, resulting in 40 articles for analysis. A systematic literature review was conducted to improve the quality of this study. Approximately 150 articles were thoroughly examined and organized using a reference manager, then 15 with the greatest impact and clinical relevance to this study were selected. Results: The HGF/C-Met complex was found to stimulate signaling pathways linked to the growth of epithelial cells and also caused the phosphorylation of tyrosine residues on other tyrosine receptors. The activation of C-Met affected the downstream pathways involving molecules associated with cell proliferation and survival, such as epidermal growth factor receptor (EGFR), p53, and KRAS. C-Met can be combined with other tyrosine kinase inhibitors in chemotherapy to enhance the initiation of cell death (apoptosis) in cancer cells.Conclusions: The HGF/C-Met mediated a signaling cascade that played an essential role in the tumorigenesis of ovarian carcinoma and had the potential to be a targeted molecular therapy in EOC","PeriodicalId":13489,"journal":{"name":"Indonesian Journal of Cancer","volume":"62 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135247676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Breast cancer patients are likely to have reduced physical activity behavior after being diagnosed. Factors associated such as sociodemographic and clinical health status have been investigated in some countries, but few studies have been conducted in Indonesia. Therefore, this study aimed to determine the sociodemographic factors and clinical health status associated with changes in physical activity behavior among breast cancer patients.Methods: A cross-sectional design was used and the samples included a total of 250 breast cancer patients at the Integrated Nuclear Medicine and Cancer Installation, Dr. Sardjito Hospital Yogyakarta. The samples were selected using the consecutive sampling method from June to July 2021, while the instruments employed had been previously tested for their validity and reliability. These included a questionnaire on the characteristics of sociodemographic and clinical health status, the Visual Analogue Scale (VAS), the Brief Fatigue Inventory (BFI), and the International Physical Activity Questionnaire Form (IPAQ-SF). This study obtained ethical clearance, while data were analyzed using chi-square and logistic regression multinominal tests with p<0.05.Results: The results showed that cancer stage (stage III: OR=2.71, 95%CI:1.14-6.45), fatigue (severe fatigue: OR=0.49, 95% CI:0.25-0.96), and pain (mild pain: OR= 27.44, 95%CI:3.20-235.18), were significantly associated with physical activity behavior in breast cancer patients. Pain as the most dominant factor (mild pain: OR=20.388, p=0.001) caused 5 times increased risk of reduced physical activity compared to others. Conclusions: Based on the results, cancer stage, fatigue, and pain were significantly related to the physical activity behavior of breast cancer patients, with pain being the most dominant factor.
{"title":"Factors Related to Physical Activity Behavior Among Breast Cancer Patients in Dr. Sardjito General Hospital Yogyakarta","authors":"Cicirosnita Jayadi Idu, Haryani Haryani, Uki Noviana","doi":"10.33371/ijoc.v17i3.989","DOIUrl":"https://doi.org/10.33371/ijoc.v17i3.989","url":null,"abstract":"Background: Breast cancer patients are likely to have reduced physical activity behavior after being diagnosed. Factors associated such as sociodemographic and clinical health status have been investigated in some countries, but few studies have been conducted in Indonesia. Therefore, this study aimed to determine the sociodemographic factors and clinical health status associated with changes in physical activity behavior among breast cancer patients.Methods: A cross-sectional design was used and the samples included a total of 250 breast cancer patients at the Integrated Nuclear Medicine and Cancer Installation, Dr. Sardjito Hospital Yogyakarta. The samples were selected using the consecutive sampling method from June to July 2021, while the instruments employed had been previously tested for their validity and reliability. These included a questionnaire on the characteristics of sociodemographic and clinical health status, the Visual Analogue Scale (VAS), the Brief Fatigue Inventory (BFI), and the International Physical Activity Questionnaire Form (IPAQ-SF). This study obtained ethical clearance, while data were analyzed using chi-square and logistic regression multinominal tests with p<0.05.Results: The results showed that cancer stage (stage III: OR=2.71, 95%CI:1.14-6.45), fatigue (severe fatigue: OR=0.49, 95% CI:0.25-0.96), and pain (mild pain: OR= 27.44, 95%CI:3.20-235.18), were significantly associated with physical activity behavior in breast cancer patients. Pain as the most dominant factor (mild pain: OR=20.388, p=0.001) caused 5 times increased risk of reduced physical activity compared to others. Conclusions: Based on the results, cancer stage, fatigue, and pain were significantly related to the physical activity behavior of breast cancer patients, with pain being the most dominant factor.","PeriodicalId":13489,"journal":{"name":"Indonesian Journal of Cancer","volume":"5 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135247953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：